Lilly Updates On Cymbalta, Zyprexa, Cialis Expected At Dec. 9 Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Cymbalta was launched for depression in August; Lilly anticipates first half 2005 approval of duloxetine for stress urinary incontinence under the Yentreve name. Patent challenges to the antipsychotic Zyprexa and Lilly’s cost-cutting efforts are also likely topics at the investor meeting.